Xin‐an Lu

1.8k total citations
45 papers, 1.4k citations indexed

About

Xin‐an Lu is a scholar working on Oncology, Molecular Biology and Organic Chemistry. According to data from OpenAlex, Xin‐an Lu has authored 45 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Oncology, 22 papers in Molecular Biology and 8 papers in Organic Chemistry. Recurrent topics in Xin‐an Lu's work include CAR-T cell therapy research (20 papers), Glycosylation and Glycoproteins Research (9 papers) and Advancements in Semiconductor Devices and Circuit Design (7 papers). Xin‐an Lu is often cited by papers focused on CAR-T cell therapy research (20 papers), Glycosylation and Glycoproteins Research (9 papers) and Advancements in Semiconductor Devices and Circuit Design (7 papers). Xin‐an Lu collaborates with scholars based in China, Taiwan and Ethiopia. Xin‐an Lu's co-authors include Shang‐Cheng Hung, Yan Fu, Suvarn S. Kulkarni, Jinq‐Chyi Lee, Yongzhang Luo, Yanping Ding, Yuh‐Sheng Wen, Lin Jia, Yang Chen and Yongzhang Luo and has published in prestigious journals such as Journal of the American Chemical Society, Journal of Biological Chemistry and Journal of Clinical Oncology.

In The Last Decade

Xin‐an Lu

41 papers receiving 1.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Xin‐an Lu China 21 776 613 348 229 160 45 1.4k
Berkley E. Gryder United States 21 1.2k 1.6× 545 0.9× 198 0.6× 41 0.2× 180 1.1× 48 1.8k
Simon Wisnovsky Canada 16 1.5k 1.9× 442 0.7× 289 0.8× 115 0.5× 38 0.2× 22 1.9k
Green Ahn United States 11 1.3k 1.7× 518 0.8× 189 0.5× 143 0.6× 51 0.3× 11 1.6k
Shigeki Jinno Japan 21 1.6k 2.1× 643 1.0× 251 0.7× 511 2.2× 124 0.8× 34 2.2k
Constantina Christodoulou United States 12 894 1.2× 211 0.3× 73 0.2× 422 1.8× 133 0.8× 15 1.8k
Sylvain Julien France 24 2.0k 2.5× 575 0.9× 413 1.2× 314 1.4× 145 0.9× 28 2.6k
Annamaria Sandomenico Italy 19 814 1.0× 241 0.4× 117 0.3× 83 0.4× 38 0.2× 82 1.3k
Hong Chang Taiwan 24 1.5k 1.9× 266 0.4× 142 0.4× 65 0.3× 151 0.9× 57 2.1k
Graziano Lolli Italy 21 1.1k 1.5× 443 0.7× 129 0.4× 210 0.9× 62 0.4× 46 1.6k
Jérôme Devy France 17 551 0.7× 173 0.3× 108 0.3× 118 0.5× 43 0.3× 43 1.2k

Countries citing papers authored by Xin‐an Lu

Since Specialization
Citations

This map shows the geographic impact of Xin‐an Lu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xin‐an Lu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xin‐an Lu more than expected).

Fields of papers citing papers by Xin‐an Lu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xin‐an Lu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xin‐an Lu. The network helps show where Xin‐an Lu may publish in the future.

Co-authorship network of co-authors of Xin‐an Lu

This figure shows the co-authorship network connecting the top 25 collaborators of Xin‐an Lu. A scholar is included among the top collaborators of Xin‐an Lu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xin‐an Lu. Xin‐an Lu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Zhang, Fenghao, Kaiping Liu, Qian Guo, et al.. (2025). MUC18-Directed chimeric antigen receptor T cells for the treatment of mucosal melanoma. Journal of Translational Medicine. 23(1). 473–473.
2.
Lu, Xin‐an, Aijun Zhang, Huaying Wang, et al.. (2025). Emerging role of the TCA cycle and its metabolites in lung disease. Frontiers in Physiology. 16. 1621013–1621013. 2 indexed citations
4.
Qi, Changsong, Chang Liu, Xiaofei Wei, et al.. (2024). Antigen-independent activation is critical for the durable antitumor effect of GUCY2C-targeted CAR-T cells. Journal for ImmunoTherapy of Cancer. 12(10). e009960–e009960. 5 indexed citations
5.
Wang, Ting, Chunli Zhang, Yanping Ding, et al.. (2024). BCMA-BBZ-OX40 CAR-T Therapy Using an Instant Manufacturing Platform in Multiple Myeloma. Journal for ImmunoTherapy of Cancer. 12(9). e009476–e009476. 4 indexed citations
6.
Wu, Mindan, Yijing Tang, Chao He, et al.. (2024). Real-World Outcomes of Pyrotinib-Based Therapy for HER2-Positive Breast Cancer With Brain Metastases: A Multicentre, Retrospective Analysis. Clinical Breast Cancer. 25(3). e249–e259. 1 indexed citations
7.
Ying, Zhitao, Ting He, Shanzhao Jin, et al.. (2022). A durable 4-1BB-based CD19 CAR-T cell for treatment of relapsed or refractory non-Hodgkin lymphoma. Chinese Journal of Cancer Research. 34(1). 53–62. 5 indexed citations
8.
Wang, Ting, Ting He, Ru Feng, et al.. (2022). Clinical Outcomes of BCMA CAR-T Cells in a Multiple Myeloma Patient With Central Nervous System Invasion. Frontiers in Oncology. 12. 854448–854448. 10 indexed citations
9.
Zhang, Xian, Junfang Yang, Jingjing Li, et al.. (2021). Factors associated with treatment response to CD19 CAR-T therapy among a large cohort of B cell acute lymphoblastic leukemia. Cancer Immunology Immunotherapy. 71(3). 689–703. 32 indexed citations
10.
Su, Tong, Zhitao Ying, Xin‐an Lu, et al.. (2020). The clinical outcomes of fresh versus cryopreserved CD19-directed chimeric antigen receptor T cells in non-Hodgkin lymphoma patients. Cryobiology. 96. 106–113. 10 indexed citations
11.
Wan, Wei, Ting He, Feifei Qi, et al.. (2019). Autologous CD19-directed chimeric antigen receptor-T cell is an effective and safe treatment to refractory or relapsed diffuse large B-cell lymphoma. Cancer Gene Therapy. 26(7-8). 248–255. 18 indexed citations
12.
Ying, Zhitao, Wen Zheng, Nan Lin, et al.. (2019). Parallel comparison of 4-1BB or CD28 co-stimulated CD19-targeted chimeric antigen receptor-T cells for B-cell non-Hodgkin lymphoma. Annals of Oncology. 30. v482–v482. 2 indexed citations
13.
Ying, Zhitao, Xiaopei Wang, Wen Zheng, et al.. (2019). Parallel Comparison of 4-1BB or CD28 Co-stimulated CD19-Targeted CAR-T Cells for B Cell Non-Hodgkin’s Lymphoma. Molecular Therapy — Oncolytics. 15. 60–68. 117 indexed citations
14.
Qian, Liren, Dan Li, Lie Ma, et al.. (2016). The novel anti-CD19 chimeric antigen receptors with humanized scFv (single-chain variable fragment) trigger leukemia cell killing. Cellular Immunology. 304-305. 49–54. 26 indexed citations
15.
Wang, Shan, Xin‐an Lu, Peng Liu, et al.. (2015). Endostatin Has ATPase Activity, Which Mediates Its Antiangiogenic and Antitumor Activities. Molecular Cancer Therapeutics. 14(5). 1192–1201. 23 indexed citations
16.
Zhuo, Wei, Lin Jia, Nan Song, et al.. (2012). The CXCL12–CXCR4 Chemokine Pathway: A Novel Axis Regulates Lymphangiogenesis. Clinical Cancer Research. 18(19). 5387–5398. 95 indexed citations
17.
Hung, Shang‐Cheng, et al.. (2011). Synthesis of heparinoligosaccharides and their interaction with eosinophil-derived neurotoxin. Organic & Biomolecular Chemistry. 10(4). 760–772. 41 indexed citations
18.
Hwang, Chi‐Shin, et al.. (2008). Characterization of Molecular Interactions between Eosinophil Cationic Protein and Heparin. Journal of Biological Chemistry. 283(37). 25468–25474. 36 indexed citations
19.
Lu, Xin‐an. (2007). Relationship between changes of the pigments content and leaf color changing in Liquidambar formosana. Journal of Northwest A & F University. 5 indexed citations
20.
Shie, Chi‐Rung, et al.. (2006). Synthesis of 48 Disaccharide Building Blocks for the Assembly of a Heparin and Heparan Sulfate Oligosaccharide Library. Organic Letters. 8(26). 5995–5998. 82 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026